Fresenius Medical Care Analyst Ratings
Fresenius Medical Care Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 39.49% | Truist Securities | $28 → $24 | Maintains | Hold |
| 07/13/2023 | 62.74% | Truist Securities | $26 → $28 | Maintains | Hold |
| 05/10/2023 | 51.12% | Truist Securities | $24 → $26 | Maintains | Hold |
| 04/13/2023 | 39.49% | Truist Securities | $22 → $24 | Maintains | Hold |
| 02/23/2023 | 27.87% | Truist Securities | $17 → $22 | Maintains | Hold |
| 06/22/2022 | 56.93% | Truist Securities | $34 → $27 | Maintains | Hold |
| 11/23/2021 | — | HSBC | Initiates Coverage On | → Hold | |
| 11/17/2021 | 103.43% | RBC Capital | $42 → $35 | Maintains | Sector Perform |
| 11/11/2021 | — | Jefferies | Upgrades | Underperform → Hold | |
| 05/21/2020 | 178.99% | SunTrust Robinson Humphrey | $46 → $48 | Maintains | Buy |
| 05/11/2020 | 167.36% | SunTrust Robinson Humphrey | $42 → $46 | Maintains | Buy |
| 04/13/2020 | 144.12% | SunTrust Robinson Humphrey | $46 → $42 | Maintains | Buy |
| 02/21/2020 | 167.36% | CFRA | $38 → $46 | Upgrades | Hold → Buy |
| 01/21/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 10/23/2019 | — | Redburn Partners | Downgrades | Buy → Neutral | |
| 08/01/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/20/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 10/26/2018 | — | UBS | Upgrades | Neutral → Buy | |
| 10/18/2018 | — | DZ Bank | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月11日 | 39.49% | Truist證券 | $28→$24 | 維護 | 保持 |
| 07/13/2023 | 62.74% | Truist證券 | $26→$28 | 維護 | 保持 |
| 2023年05月10日 | 51.12% | Truist證券 | $24→$26 | 維護 | 保持 |
| 04/13/2023 | 39.49% | Truist證券 | $22→$24 | 維護 | 保持 |
| 02/23/2023 | 27.87% | Truist證券 | $17→$22 | 維護 | 保持 |
| 2022/06/22 | 56.93% | Truist證券 | $34→$27 | 維護 | 保持 |
| 2021年11月23日 | - | 匯豐銀行 | 開始承保 | →保留 | |
| 2021年11月17日 | 103.43% | 加拿大皇家銀行資本 | $42→$35 | 維護 | 行業表現 |
| 2021年11月11日 | - | 傑富瑞 | 升級 | 表現不佳的→保持 | |
| 2020/05/21 | 178.99% | SunTrust Robinson Humphrey | $46→$48 | 維護 | 買 |
| 05/11/2020 | 167.36% | SunTrust Robinson Humphrey | $42→$46 | 維護 | 買 |
| 04/13/2020 | 144.12% | SunTrust Robinson Humphrey | $46→$42 | 維護 | 買 |
| 02/21/2020 | 167.36% | CFRA | $38→$46 | 升級 | 持有→購買 |
| 2020/01/21 | - | 傑富瑞 | 升級 | 持有→購買 | |
| 2019年10月23日 | - | Redburn合作夥伴 | 評級下調 | 購買→中性 | |
| 2019年08月01日 | - | BTIG | 評級下調 | 購買→中性 | |
| 2019年06月20日 | - | 巴克萊 | 升級 | 等重→超重 | |
| 2018年10月26日 | - | 瑞銀集團 | 升級 | 中性→購買 | |
| 2018年10月18日 | - | 德國中央合作銀行 | 評級下調 | 購買→Hold |
What is the target price for Fresenius Medical Care (FMS)?
費森尤斯醫療保健(FMS)的目標價格是多少？
The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $24.00 expecting FMS to rise to within 12 months (a possible 39.49% upside). 5 analyst firms have reported ratings in the last year.
TRUIST證券於2023年10月11日報道了費森尤斯醫療保健公司(紐約證券交易所代碼：FMS)的最新目標價。這家分析公司將目標價定為24美元，預計FMS將在12個月內上漲至39.49%。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Fresenius Medical Care (FMS)?
費森尤斯醫療保健(FMS)的最新分析師評級是多少？
The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.
費森尤斯醫療保健公司(紐約證券交易所代碼：FMS)的最新分析師評級由Truist Securities提供，費森尤斯醫療保健公司維持其持有評級。
When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?
費森尤斯醫療保健(FMS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與費森尤斯醫療保健公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。費森尤斯醫療保健的上一次評級是在2023年10月11日提交的，因此您應該預計下一次評級將在2024年10月11日左右提供。
Is the Analyst Rating Fresenius Medical Care (FMS) correct?
分析師對費森尤斯醫療保健(FMS)的評級正確嗎？
While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $28.00 to $24.00. The current price Fresenius Medical Care (FMS) is trading at is $17.20, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的費森尤斯醫療保健(FMS)評級保持不變，目標價在28.00美元至24.00美元之間。費森尤斯醫療保健(FMS)目前的交易價格為17.20美元，超出了分析師的預測範圍。